免疫检查点抑制剂相关肝毒性的临床特征与不良影响
该研究纳入2010年1月至2018年3月接受免疫检查点抑制剂(ICI)治疗的5762例患者,肝毒性定义为ALT>5倍正常上限且无其他原因。100例(2%)发生肝毒性,联合治疗组比例(9.2%)高于单药治疗组(最高1.7%,P<0.001)。多数患者永久停用ICI,部分患者重启ICI后未再发肝毒性。
要点
- ICI相关肝毒性发生率为2%,联合治疗组高于单药治疗组。
- 肝毒性导致多数患者永久停用ICI。
- 重启ICI后仅少数患者肝毒性复发。
核心结论
- ICI相关临床显著肝毒性不常见,但可导致多数患者永久停用ICI;重启ICI后多数患者未再发肝毒性。
研究设计与样本
- 回顾性研究,纳入2010年1月1日至2018年3月31日接受ICI(单药或联合)治疗的5762例患者。
主要发现
- 5762例中100例(2%)发生肝毒性,联合治疗组发生率为9.2%,单药治疗组最高为1.7%(P<0.001)。
- 31例在ALT改善后重启ICI,其中8例(26%)肝毒性复发。
- 38例可能患有基础肝病者与62例无基础肝病者的肝损伤特征、激素反应及结局相似。
- 联合治疗与单药治疗的肝毒性严重程度及结局无显著差异;共36例死亡,其中2例死亡时存在肝衰竭(均伴肝转移进展和3级肝毒性)。
关键数值与推荐
- 肝毒性定义为ALT>5倍正常上限且无其他原因。
- 根据CTCAE 4.03分级:3级为ALT 5-20倍正常上限,4级为ALT>20倍正常上限。
临床怎么用
- 对接受ICI治疗的患者应监测肝功能,尤其联合治疗者。
- 发生肝毒性后多数需永久停用ICI,但部分患者可在ALT改善后重启且未再发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We conducted this study to characterize the incidence, clinical features, treatment, and outcomes of immune checkpoint inhibitor (ICI) hepatotoxicity. METHODS: Patients who received ICIs (with either single-agent or combination regimens) from January 1, 2010, to March 31, 2018, were identified. Hepatotoxicity was defined as alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN), in the absence of an alternate cause, and categorized as grade 3 (ALT 5-20× ULN) or grade 4 (ALT >20× ULN), according to Common Terminology Criteria for Adverse Events 4.03. RESULTS: Among 5,762 patients, 100 (2%) developed hepatotoxicity, occurring in a higher proportion of recipients of combination therapy (9.2%) compared with monotherapy (up to 1.7%, P < 0.001). ICIs were discontinued permanently in 69 and temporarily in 31 patients. Sixty-seven patients received steroids, 10 of whom (14%) had recurrent hepatotoxicity after the steroid taper. Thirty-one patients resumed ICIs after ALT improvement, 8 of whom (26%) developed recurrent hepatotoxicity. Characteristics of liver injury, response to steroids, and outcomes were similar between 38 individuals with and 62 without possible pre-existing liver disease. The severity and outcome of hepatotoxicity due to combination therapy were not significantly different from monotherapy. There were 36 deaths. Two had liver failure at the time of death, both with progression of liver metastases and grade 3 hepatotoxicity. DISCUSSION: Clinically significant ICI-related hepatotoxicity was uncommon but led to permanent ICI discontinuation in the majority. ICIs were restarted in a sizable proportion of patients, most of whom did not experience recurrent hepatotoxicity.
引用
- Miller ED, Abu-Sbeih H, Styskel B, et al. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. Am J Gastroenterol. 2020. PMID: 31789632. doi:10.14309/ajg.0000000000000398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。